Tumour localisation with a radioactively labelled reshaped human monoclonal antibody
1991

Using a Human Monoclonal Antibody to Locate Tumors

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): V. Hird, M. Verhoeyen, R.A. Badley, D. Price, D. Snook, C. Kosmas, C. Gooden, A. Bamias, C. Meares, J.P. Lavender, A.A. Epenetos

Primary Institution: Imperial Cancer Research Fund Oncology Group, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London

Hypothesis

Can a reshaped human monoclonal antibody effectively localize tumors in patients with malignant disease?

Conclusion

The reshaped human monoclonal antibody successfully localized to tumors in patients with antigen positive malignant disease without causing toxicity.

Supporting Evidence

  • Four out of seven patients showed successful tumor localization.
  • No toxicity was observed in any of the patients.
  • Three out of six patients developed an immune response against the macrocycle DOTA.

Takeaway

Doctors used a special human-made antibody to find tumors in sick people, and it worked well without making them feel worse.

Methodology

The study involved imaging patients with a radiolabelled human monoclonal antibody and assessing its localization to tumors.

Potential Biases

Potential bias due to prior exposure to murine antibodies in some patients.

Limitations

The study had a small sample size and some patients had pre-existing immune responses that could affect results.

Participant Demographics

Patients aged between 36 and 65 years, with prior surgery and chemotherapy for malignant disease.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication